To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors

Abstract

The generation of immunological memory is a hallmark of adaptive immunity by which the immune system "remembers" a previous encounter with an antigen expressed by pathogens, tumors, or normal tissues; and, upon secondary encounters, mounts faster and more effective recall responses. The establishment of T cell memory is influenced by both cell-intrinsic and cell-extrinsic factors, including genetic, epigenetic and environmental triggers. Our current knowledge of the mechanisms involved in memory T cell differentiation has instructed new opportunities to engineer T cells with enhanced anti-tumor activity. The development of adoptive T cell therapy has emerged as a powerful approach to cure a subset of patients with advanced cancers. Efficacy of this approach often requires long-term persistence of transferred T cell products, which can vary according to their origin and manufacturing conditions. Host preconditioning and post-transfer supporting strategies have shown to promote their engraftment and survival by limiting the competition with a hostile tumor microenvironment and between pre-existing immune cell subsets. Although in the general view pre-existing memory can confer a selective advantage to adoptive T cell therapy, here we propose that also "bad memories"-in the form of antigen-experienced T cell subsets-co-evolve with consequences on newly transferred lymphocytes. In this review, we will first provide an overview of selected features of memory T cell subsets and, then, discuss their putative implications for adoptive T cell therapy.

Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers

“… 35 , 36 The suppressive environment may extend to nearby organs and prevail over a period of time. 37 , 38 …”

“…35,36 The suppressive environment may extend to nearby organs and prevail over a period of time. 37,38 Associations of hepatobiliary cancers with small intestinal and pancreatic cancers do not seem to be explainable by known environmental risk factors. For small intestinal cancer, high unidirectional associations were observed with gallbladder and biliary tract cancers but also with HCC.…”

Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma

“…This is particular important as there is increasing evidence that the presence of bystander T cells in the tumor microenvironment may play an important role in mediating cellular immune responses against tumor [34][35][36]. The concept of cooperation with the adoptive immune cells (whether specific or bystander cells) with endogenous antigen-specific cytotoxic cells that turn the tumor microenvironment to a controlled tumor growth microenvironment is probably more realistic, particular in the era of immune checkpoint blockade therapy [37]. Many have suggested that the bystander killing of CD8+ T cells is driven by the cytokine stimulation in conjunction with NK surface receptor-mediated killing.…”

Biomarkers and potential targets for immune and cellular therapy in triple negative breast cancer

“…The use of individual fractions of donor immune cells (primarily lymphocytes) for the adoptive therapy of solid cancers is considered. However, the authors express doubts about the duration of the therapeutic effects of adoptive immunotherapy [95]. It is possible that adoptive immunotherapy will find its place in combined regimens for the treatment of solid tumors, along with targeted drugs.…”